Expertise in
11
conditions

Richard W. Keen

London, ENG, GB 
Expertise in
11
conditions
London, ENG, GB 

Overview

Richard Keen practices practicing medicine in London, United Kingdom.

Mr. Keen is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Fibrodysplasia Ossificans Progressiva, Hypophosphatemia, Rickets, and X-Linked Hypophosphatemia.

He is actively involved in clinical research, co-authoring 61 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

London, ENG, United Kingdom
Other Locations
Stanmore, ENG HA74LP, United Kingdom
Brockley Hill, Stanmore, Middlesex, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Enrollment Status: Completed
Publish Date: June 11, 2026
Intervention Type: Drug
Study Drugs: Teriparatide, Zoledronic Acid
Study Phase: Phase 4
A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Palovarotene
Study Phase: Phase 2
A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Completed
Publish Date: November 29, 2023
Intervention Type: Drug
Study Drug: Palovarotene
Study Phase: Phase 3
Development of a Novel, Safe Method for the Non-invasive Assessment of Human Bone Quality, In Vivo, Using Spatially Offset Raman Spectroscopy
Development of a Novel, Safe Method for the Non-invasive Assessment of Human Bone Quality, In Vivo, Using Spatially Offset Raman Spectroscopy
Enrollment Status: Unknown
Publish Date: November 23, 2022
Intervention Type: Device
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: May 20, 2022
Intervention Type: Drug
Study Drug: Burosumab
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Completed
Publish Date: February 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Completed
Publish Date: June 26, 2020
View 7 Less Clinical Trials

61 Total Publications

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
Journal: JAMA
Published: May 14, 2026

Frequently Asked Questions about Richard W. Keen

Is Richard W. Keen a top-rated expert for Fibrodysplasia Ossificans Progressiva?

MediFind is an objective health platform that identifies experts based on real-world data. Richard W. Keen is classified as an Elite expert for Fibrodysplasia Ossificans Progressiva, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Richard W. Keen participate in research or clinical trials?

Yes. Richard W. Keen has published 61 articles and abstracts on conditions like Fibrodysplasia Ossificans Progressiva. You can view a list of Richard W. Keen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Keen's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile